DRUGS & SUPPLEMENTS
What are the side effects you encounter while taking this medicine?
CNS stimulants, including Rubifen, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy .
WARNING: ABUSE AND DEPENDENCE
See full prescribing information for complete boxed warning.
Rubifen is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age .
Rubifen is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. (1)
Prior to initiating treatment with Rubifen, assess for the presence of cardiac disease (i.e. perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) .
Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy. Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for Rubifen use .
Rubifen is given orally once daily in the morning.
Advise patients to take Rubifen consistently either with food or without food .
The recommended starting dose of Rubifen for patients 6 to 17 years of age is 17.3 mg once daily in the morning. The dose may be titrated weekly in increments of 8.6 mg to 17.3 mg. Daily doses above 51.8 mg have not been studied and are not recommended.
The dose should be individualized according to the needs and responses of the patient.
Pharmacological treatment of ADHD may be needed for extended periods. Periodically re-evaluate the long-term use of Rubifen and adjust dosage as needed.
If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or, if necessary, discontinue the drug. Rubifen should be periodically discontinued to assess the child's condition. If improvement is not observed after appropriate dosage adjustment over a one-month period, discontinue the drug.
Instruct the patient or caregiver on the following administration instructions:
Extended-Release Orally Disintegrating Tablets: 8.6 mg, 17.3 mg and 25.9 mg. (3)
Rubifen is contraindicated in patients with:
CNS stimulants, including Rubifen, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy .
Sudden death, stroke and myocardial infarction have occurred in adults treated with CNS stimulants at recommended doses. Sudden death has occurred in pediatric patients with structural cardiac abnormalities and other serious cardiac problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems. Perform further evaluation on patients who develop exertional chest pain, unexplained syncope, or arrhythmias during Rubifen treatment.
CNS stimulants cause an increase in blood pressure and heart rate (mean increase approximately 3 to 6 bpm). Individuals may have larger increases. Monitor all patients for hypertension and tachycardia.
Exacerbation of Pre-Existing Psychosis
CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.
Induction of a Manic Episode in Patients with Bipolar Disorder
CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g. comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).
New Psychotic or Manic Symptoms
CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking or mania) in patients without a prior history of psychotic illness or mania. If such symptoms occur, consider discontinuing Rubifen. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared to 0 in placebo-treated patients.
Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with Rubifen products in both pediatric and adult patients. Priapism was not reported with drug initiation but developed after some time on the drug, often subsequent to an increase in dose. Priapism has also appeared during a period of drug withdrawal. Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.
CNS stimulants, including Rubifen, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.
CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.
Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who were randomized to either Rubifen or nonmedication-treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and nonmedication-treated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e. treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development.
Closely monitor growth (weight and height) in pediatric patients treated with CNS stimulants, including Rubifen. Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.
The following are discussed in more detail in other sections of the labeling:
Based on accumulated data from other Rubifen products, the most common (>5% and twice the rate of placebo) adverse reactions are appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, and blood pressure increased. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Neos Therapeutics, Inc. at 1-888-319-1789 or http://www. COTEMPLAXRODT.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Clinical Trials Experience with Other Rubifen Products in Children, Adolescents, and Adults with ADHD
Commonly reported (≥2% of the Rubifen group and at least twice the rate of the placebo group) adverse reactions from placebo-controlled trials of Rubifen products include: appetite decreased, weight decreased, nausea, abdominal pain, dyspepsia, dry mouth, vomiting, insomnia, anxiety, nervousness, restlessness, affect lability, agitation, irritability, dizziness, vertigo, tremor, blurred vision, blood pressure increased, heart rate increased, tachycardia, palpitations, hyperhidrosis, and pyrexia.
Clinical Trials Experience with Rubifen in Children with ADHD
There is limited experience with Rubifen in controlled trials. Based on this limited experience, the adverse reaction profile of Rubifen appears similar to other Rubifen extended release-products.
The following adverse reactions have been identified during post approval use of Rubifen products. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions are as follows:
Blood and Lymphatic System Disorders: Pancytopenia, Thrombocytopenia, Thrombocytopenic purpura
Cardiac Disorders: Angina pectoris, Bradycardia, Extrasystole, Supraventricular tachycardia, Ventricular extrasystole
Eye Disorders: Diplopia, Mydriasis, Visual impairment
General Disorders: Chest pain, Chest discomfort, Hyperpyrexia
Immune System Disorders: Hypersensitivity reactions such as Angioedema, Anaphylactic reactions, Auricular swelling, Bullous conditions, Exfoliative conditions, Urticarias, Pruritis NEC, Rashes, Eruptions, and Exanthemas NEC
Investigations: Alkaline phosphatase increased, Bilirubin increased, Hepatic enzyme increased, Platelet count decreased, White blood cell count abnormal
Musculoskeletal, Connective Tissue and Bone Disorders: Arthralgia, Myalgia, Muscle twitching, Rhabdomyolysis
Nervous System Disorders: Convulsion, Grand mal convulsion, Dyskinesia, Serotonin syndrome in combination with serotonergic drugs
Psychiatric Disorders: Disorientation, Hallucination, Hallucination auditory, Hallucination visual, Libido changes, Mania
Urogenital System: Priapism
Skin and Subcutaneous Tissue Disorders: Alopecia, Erythema
Vascular Disorders: Raynaud's phenomenon
|Monoamine Oxidase Inhibitors (MAOI)|
|Clinical Impact:||Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure .|
|Intervention:||Do not administer COTEMPLA-XR ODT concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment.|
|Examples:||selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue|
|Gastric pH Modulators|
|Clinical Impact:||May change the release profile and alter the pharmacodynamics of COTEMPLA-XR ODT.|
|Intervention:||Concomitant use of Rubifen with a gastric pH modulator (i.e., a H2-blocker or a proton pump inhibitor) is not recommended.|
|Examples:||omeprazole, famotidine, sodium bicarbonate|
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Rubifen during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388.
Published studies and postmarketing reports on Rubifen use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes . There are risks to the fetus associated with the use of central nervous system stimulants during pregnancy . No teratogenic effects were observed in embryo-fetal development studies with oral administration of Rubifen to pregnant rats and rabbits during organogenesis at doses 4 and 18 times, respectively, the maximum recommended human dose (MRHD) of 51.8 mg (as base). However, spina bifida was observed in rabbits at a dose 60 times the MRHD .
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Fetal/Neonatal adverse reactions
CNS stimulants, such as Rubifen, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of therapeutic doses of Rubifen during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers.
A limited number of pregnancies have been reported in published observational studies and postmarketing reports describing Rubifen use during pregnancy. Due to the small number of methylphenidate-exposed pregnancies with known outcomes, these data cannot definitely establish or exclude any drug-associated risk during pregnancy. Methodological limitations of these observational studies include small sample size, concomitant use of other medications, lack of detail regarding dose and duration of exposure to Rubifen and non-generalizability of the enrolled populations.
In studies conducted in rats and rabbits, Rubifen was administered orally at doses of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Teratogenic effects (increased incidence of fetal spina bifida) were observed in rabbits at the highest dose, which is approximately 60 times the maximum recommended human dose (MRHD) of 51.8 mg (as base) for adolescents on a mg/m2 basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (18 times the MRHD for adolescent on a mg/m2 basis). There was no evidence of specific teratogenic activity in rats, although increased incidences of fetal skeletal variations were seen at the highest dose level (11 times the MRHD on a mg/m2 basis for adolescent), which was also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (4 times the MRHD on a mg/m2 basis for adolescent).
Limited published literature, based on breast milk sampling from five mothers, reports that Rubifen is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Rubifen and any potential adverse effects on the breastfed child from Rubifen or from the underlying maternal condition.
Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain.
The safety and effectiveness of Rubifen have been established in pediatric patients 6 to 17 years of age in one adequate and well-controlled study in pediatric patients 6 to 12 years, pharmacokinetic data in adolescents, and safety information from other methyphenidate-containing products .
The long-term efficacy of Rubifen in pediatric patients has not been established. Safety and effectiveness of Rubifen in pediatric patients below 6 years of age have not been established.
Long Term Suppression Growth
Growth should be monitored during treatment with stimulants, including Rubifen. Children who are not growing or gaining weight as expected may need to have their treatment interrupted .
Juvenile Animal Toxicity Data
Rats treated with Rubifen early in the postnatal period through sexual maturation demonstrated a decrease in spontaneous locomotor activity in adulthood. A deficit in acquisition of a specific learning task was observed in females only. The doses at which these findings were observed are at least 6 times the maximum recommended human dose (MRHD) of 51.8 mg (as base) for pediatric patients on a mg/m2 basis.
In the study conducted in young rats, Rubifen was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal day 7) and continuing through sexual maturity (postnatal week 10). When these animals were tested as adults (postnatal weeks 13-14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day [approximately 6 times the MRHD of 51.8 mg (as base) on a mg/m2 basis] or greater, and a deficit in the acquisition of a specific learning task was observed in females exposed to the highest dose (12 times the MRHD on a mg/m2 basis). The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (half the MRHD on a mg/m2 basis). The clinical significance of the long-term behavioral effects observed in rats is unknown.
Rubifen has not been studied in patients over the age of 65 years.
Rubifen contains Rubifen, a Schedule II controlled substance.
CNS stimulants including Rubifen, other methylphenidate-containing products, and amphetamines have a high potential for abuse. Abuse is characterized by impaired control over drug use, compulsive use, continued use despite harm, and craving.
Signs and symptoms of CNS stimulant abuse include increased heart rate, respiratory rate, blood pressure, and/or sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss of coordination, tremors, flushed skin, vomiting, and/or abdominal pain. Anxiety, psychosis, hostility, aggression, suicidal or homicidal ideation have also been observed. Abusers of CNS stimulants may chew, snort, inject, or use other unapproved routes of administration which can result in overdose and death .
To reduce the abuse of CNS stimulants including Rubifen, assess the risk of abuse prior to prescribing. After prescribing, keep careful prescription records educate patients and their families about abuse and on proper storage and disposal of CNS stimulants , monitor for signs of abuse while on therapy, and re-evaluate the need for Rubifen use.
Tolerance (a state of adaptation in which exposure to a drug results in a reduction of the drug's desired and/or undesired effects over time) can occur during chronic therapy with CNS stimulants including Rubifen.
Physical dependence (a state of adaptation manifested by a withdrawal syndrome produced by abrupt cessation, rapid dose reduction, or administration of an antagonist) can occur in patients treated with CNS stimulants including Rubifen. Withdrawal symptoms after abrupt cessation following prolonged high-dosage administration of CNS stimulants include dysphoric mood; depression, fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.
Signs and symptoms of acute Rubifen overdosage, resulting principally from overstimulation of the CNS and from excessive sympathomimetic effects, may include the following: nausea, vomiting, diarrhea, restlessness, anxiety, agitation, tremors, hyperflexia, muscle twitching, convulsion, euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, hypotension, tachypnea, mydriasis, dryness of mucous membranes, and rhabdomyolysis.
Consult with a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice on the management of overdosage with Rubifen. Provide supportive care, including close medical supervision and monitoring. Treatment should consist of general measures employed in the management of overdosage with any drug. Consider the possibility of multiple drug overdosage. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. Use supportive and symptomatic measures.
Rubifen contains Rubifen, a central nervous system (CNS) stimulant. Rubifen is an extended-release orally disintegrating tablet intended for once daily administration. Rubifen contains approximately 25% immediate-release and 75% extended-release Rubifen. Rubifen is ionically-bound to the sulfonate of polystyrene sulfonate particles.
Rubifen contains 8.6 mg, 17.3 mg or 25.9 mg of Rubifen which is the same as the amount of Rubifen (base equivalent) found, respectively, in 10 mg, 20 mg and 30 mg strength Rubifen hydrochloride products.
The chemical name of Rubifen is methyl α-phenyl-2-piperidineacetate, and its structural formula is shown in Figure 1.
Figure 1: Methylphenidate Structure
C14H19NO2 Mol. Wt. 233.31
Rubifen also contains the following inactive ingredients: Mannitol, Fructose, Microcrystalline Cellulose, Crospovidone, Methacrylic Acid, Polystyrene Sulfonate, Citric Acid, Colloidal Silicon Dioxide, Grape Flavor, Natural Masking Type Powder, Triethyl Citrate, Magnesium Stearate, Ethylcellulose, Sucralose, Lake Blend Purple, and Polyethylene Glycol.
Rubifen is a central nervous system stimulant. The mode of therapeutic action in ADHD is not known.
Rubifen is a racemic mixture comprised of the d- and 1-isomers. The d-isomer is more pharmacologically active than the l-isomer. Rubifen is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
After oral administration of Rubifen, circulation levels of l- Rubifen (MPH) were about 2% of total MPH.
Following a single dose of 51.8 mg (2×25.9 mg daily) Rubifen in healthy adult subjects under fasted conditions, plasma Rubifen (MPH) reached maximal concentration (Cmax) at a median time of 5 hours after dosing. Compared to an extended release capsule formulation of Rubifen, Rubifen mean Cmax and exposure (AUCinf) was about 26% and 6% higher, respectively, after Rubifen administration (Figure 2).
Figure 2: Mean d-Rubifen Plasma Concentration-Time Profiles After Administration of Rubifen or Rubifen Hydrochloride Extended-Release Capsule in Healthy Volunteers Under Fasted Conditions
Effect of Food
Administration of 51.8 mg Rubifen with food (a high fat meal) decreased the Cmax and increased AUCinf of total MPH by approximately 24% and 16%, respectively. Food shortened the median time to peak concentration (Tmax) by 0.5 hour (fed: 4.5 hours vs. fasted: 5.0 hours).
Effect of Alcohol
There is no in vivo study conducted for the effect of alcohol on drug exposure. An in vitro dissolution study showed alcohol-induced dose dumping potential in the presence of 40% alcohol. Dose dumping was not observed in the presence of lower alcohol concentrations.
Plasma Rubifen concentrations decline monophasically following oral administration of Rubifen. The mean plasma terminal elimination half-life of Rubifen was about 4 hours in healthy volunteers following a single 51.8 mg dose administration.
In humans, Rubifen is metabolized primarily via deesterification to alpha-phenyl-piperidine acetic acid (ritalinic acid). The metabolite has little or no pharmacological activity.
After oral dosing of radiolabeled Rubifen in humans, about 90% of the radioactivity was recovered in urine. The main primary metabolite was PPAA, accounting for approximately 80% of the dose.
Male and Female Patients and Ethnic Groups
There is insufficient experience with the use of Rubifen to detect gender or ethnic variations in pharmacokinetics.
The pharmacokinetics of Rubifen after Rubifen administration were studied in pediatric patients (6-17 years of age) with ADHD under fasted conditions. After a single oral dose of 51.8 mg Rubifen, plasma concentrations of Rubifen in children (6-12 years of age) were approximately twice the concentrations observed in adults. Exposure levels in adolescent patients (13 -17 years of age) were similar to those in adults. Body weight normalized clearance values were similar across the age groups (Table 2).
|PK Parameter||Children (n=24)||Adolescent (n=8)||Adult (n=38)|
|Tmax (hr) ||4.6 (2.0-8.0)||5.31 (3.5-8.0)||4.98 (2.5 – 6.5)|
Patients with Renal Impairment
There is no experience with the use of Rubifen in patients with renal insufficiency. After oral administration of radiolabeled Rubifen in humans, Rubifen was extensively metabolized and approximately 80% of the radioactivity was excreted in the urine in the form of PPAA. Since renal clearance is not an important route of Rubifen clearance, renal insufficiency is expected to have little effect on the pharmacokinetics of Rubifen.
Patients with Hepatic Impairment
There is no experience with the use of Rubifen in patients with hepatic insufficiency.
In a lifetime carcinogenicity study carried out in B6C3F1 mice, Rubifen caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas at a daily dose of approximately 60 mg/kg/day. For pediatric patients, this dose is approximately 4 times the maximum recommended human dose of 51.8 (as base) on a mg/m2 basis. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors, and the significance of these results to humans is unknown.
Rubifen did not cause any increase in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dose used was approximately 45 mg/kg/day, which is approximately 5 times the maximum recommended dose of 51.8 mg (as base) for pediatric patients on a mg/m2 basis.
Rubifen was not mutagenic in the in vitro Ames reverse mutation assay or the in vitro mouse lymphoma cell forward mutation assay. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an in vitro assay in cultured Chinese Hamster Ovary (CHO) cells. Rubifen was negative in an in vivo mouse bone marrow micronucleus assay.
Impairment of Fertility
Rubifen did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week Continuous Breeding study. The study was conducted at doses up to 160 mg/kg/day, approximately 12-fold the maximum recommended human dose of 51.8 (as base) for adolescents on a mg/m2 basis.
The efficacy of Rubifen was evaluated in a laboratory classroom study conducted in 87 pediatric patients (Aged 6 to 12 years) with ADHD. Following washout of previous Rubifen medication, there was an open-label dose-optimization period (4 weeks) with an initial dose of 17.3 mg of Rubifen once daily in the morning. The dose could be titrated on a weekly basis from 17.3 mg, to 25.9 mg, to 34.6 mg, and up to 51.8 mg until an optimal dose or the maximum dose of 51.8 mg/day was reached. At the end of this period, subjects remained on their optimized dose for an additional week. Subjects then entered a 1-week randomized, double-blind, parallel group treatment period with the individually optimized dose of Rubifen or placebo. At the end of this week, raters evaluated the attention and behavior of the subjects in a laboratory classroom setting, using the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) rating scale SKAMP is a validated 13-item teacher-rated scale that assesses manifestations of ADHD in a classroom setting.
The primary efficacy endpoint was the average of the SKAMP-Combined (Attention and Deportment) scores over the test day (not including the baseline score), with assessments conducted at baseline, and 1, 3, 5, 7, 10, 12, and 13 hours post-dosing. The key secondary efficacy endpoints were onset and duration of effect, defined as the first point at which active drug separated from placebo on SKAMP-Combined scores and the last time point at which active drug separated from placebo on SKAMP-Combined scores, respectively.
The SKAMP-Combined scores test day average was statistically significantly lower (improved) with Rubifen compared to placebo (difference of -11 (95% CI: -13.9, -8.2)) (Table 3).
|Study Number||Treatment Group||Baseline Score at Randomization ||Pre-dose Score on Classroom Day ||LS Mean ||Placebo-subtracted Difference |
|SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval.|
|Study 1||Rubifen |
|21.1 (9.56)||26.8 (11.52)||14.3 (1.07)||-11.0 (-13.9, -8.2)|
|Placebo||20.4 (9.09)||19.1 (11.04)||25.3 (1.16)||--|
The SKAMP-Combined scores were also statistically significantly lower (improved) at time points (1, 3, 5, 7, 10, 12 hours) post-dosing with Rubifen compared to placebo (Figure 3).
Figure 3: LS Mean SKAMP Combined Score After Treatment with Rubifen or Placebo During Classroom Day in Patients with ADHD
*SE = Standard Error
The database was not large enough to assess whether there were differences in effects in age, gender, or race subgroups.
Rubifen Extended Release Orally Disintegrating Tablets are available in three strengths:
They are available as follows:
|NDC 70165-100-30||8.6 mg tablets: carton containing 5 blister cards of 6 tablets each, for a total of 30 tablets with a reusable travel case.|
|NDC 70165-200-30||17.3 mg tablets: carton containing 5 blister cards of 6 tablets each, for a total of 30 tablets with a reusable travel case.|
|NDC 70165-300-30||25.9 mg tablets: carton containing 5 blister cards of 6 tablets each, for a total of 30 tablets with a reusable travel case.|
Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F).
Store Rubifen blister packages in the reusable travel case after removal from the carton.
Comply with local laws and regulations on drug disposal of CNS stimulants. Dispose of remaining, unused, or expired Rubifen by a medicine take-back program or by an authorized collector registered with the Drug Enforcement Administration. If no take-back program or authorized collector is available, mix Rubifen with an undesirable, nontoxic substance to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and discard Rubifen in the household trash.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Controlled Substance Status/Potential for Abuse and Dependence
Advise patients and their caregivers that Rubifen is a federally controlled substance, and it can be abused or lead to dependence . Instruct patients that they should not give Rubifen to anyone else. Advise patients to store Rubifen in a safe place, preferably locked, to prevent abuse. Advise patients and their caregivers to comply with laws and regulations on drug disposal. Advise patients and their caregivers to dispose of remaining, unused, or expired Rubifen through a medicine take-back program if available .
Instructions for Taking Rubifen
Instruct patients and their caregivers on the following:
Serious Cardiovascular Risks
Advise patients, caregivers, and their family members that there is a potential for serious cardiovascular risks including sudden death, myocardial infarction, and stroke with Rubifen. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease .
Blood Pressure and Heart Rate Increases
Advise patients and their caregivers that Rubifen can elevate blood pressure and heart rate .
Advise patients and their caregivers that Rubifen, at recommended doses, can cause psychotic or manic symptoms, even in patients without a prior history or psychotic symptoms or mania .
Advise patients, caregivers, and family members of the possibility of painful or prolonged penile erections (priapism). Instruct the patient to seek immediate medical attention in the event of priapism .
Circulation Problems in Fingers and Toes [Peripheral vasculopathy, including Raynaud's phenomenon]
Suppression of Growth
Advise patients, families, and caregivers that Rubifen can cause slowing of growth and weight loss .
Advise patients to avoid alcohol while taking Rubifen. Consumption of alcohol while taking Rubifen may result in a more rapid release of the dose of Rubifen .
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in females exposed to Rubifen during pregnancy .
Manufactured for Neos Therapeutics Brands, LLC. Grand Prairie, TX 75050. Made in USA.
For more information, call 1-(888)-319-1789
Rubifen is a registered trademark of Neos Therapeutics, Inc.
Copyright© 2014, Neos Therapeutics, Inc.
Item # PIN010299
|This Medication Guide has been approved by the U.S. Food and Drug Administration||Revised June/2017|
| Medication Guide |
Rubifen (koh-TEM-pluh - oh dee tee)
extended-release orally disintegrating tablets, CII
| What is the most important information I should know about Rubifen? |
|Rubifen can cause serious side effects, including: |
|What is Rubifen?|
|Rubifen is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 to 17 years of age. Rubifen may help increase attention and decrease impulsiveness and hyperactivity in children 6 to 17 years of age with ADHD.|
|It is not known if Rubifen is safe and effective in children under 6 years of age.|
|Rubifen is a federally controlled substance (CII) because it contains Rubifen that can be a target for people who abuse prescription medicines or street drugs. Keep Rubifen in a safe place to protect it from theft. Never give your Rubifen to anyone else, because it may cause death or harm them. Selling or giving away Rubifen may harm others and is against the law.|
|Do not give Rubifen to your child if they are: |
| Before taking Rubifen tell your child's healthcare provider about all medical conditions, including if your |
|Tell your healthcare provider about all of the medicines that your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.|
|Rubifen and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted during treatment with Rubifen.|
|Your healthcare provider will decide whether Rubifen can be taken with other medicines. Especially tell your healthcare provider if your child takes: |
|Know the medicines that your child takes. Keep a list of the medicines with you to show your healthcare provider and pharmacist. Do not start any new medicine during treatment with Rubifen without talking to your healthcare provider first.|
| How should Rubifen be taken? |
|Take Rubifen as follows:|
|What should I avoid during treatment with Rubifen?|
|You should avoid drinking alcohol during treatment with Rubifen.|
|What are possible side effects of Rubifen?|
|Rubifen can cause serious side effects, including: |
|The most common side effects of Rubifen products include:|
| || |
|These are not all the possible side effects of Rubifen.|
|Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.|
| How should I store Rubifen? |
|Keep Rubifen and all medicines out of the reach of children.|
|General information about the safe and effective use of Rubifen|
|Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not use Rubifen for a condition for which it was not prescribed. Do not give Rubifen to other people, even if they have the same condition. It may harm them and it is against the law. You can ask your healthcare provider or pharmacist for information about Rubifen that was written for healthcare professionals.|
|What are the ingredients in Rubifen?|
|Active Ingredient: Rubifen|
|Inactive Ingredients: Mannitol, Fructose, Microcrystalline Cellulose, Crospovidone, Methacrylic Acid, Polystyrene Sulfonate, Citric Acid, Colloidal Silicon Dioxide, Grape Flavor, Natural Masking Type Powder, Triethyl Citrate, Magnesium Stearate, Ethylcellulose, Sucralose, Lake Blend Purple, and Polyethylene Glycol|
|Manufactured for Neos Therapeutics Brands, LLC, Grand Prairie, TX 75050|
|For more information go to http://www. COTEMPLAXRODT.com or call 1-888-319-1789|
|Rubifen is registered in the US Patent and Trademark Office © 2014 Neos Therapeutics, Inc.|
Depending on the reaction of the Rubifen after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Rubifen not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Rubifen addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
|Twice in a day||1||100.0%|
|> 3 month||1||100.0%|
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology